Piper Sandler Reaffirms “Overweight” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Piper Sandler restated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday, Benzinga reports. They currently have a $205.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on SRPT. Evercore ISI boosted their price target on shares of Sarepta Therapeutics from $139.00 to $185.00 and gave the stock an in-line rating in a research note on Monday, June 24th. Cantor Fitzgerald restated a neutral rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 21st. Needham & Company LLC restated a buy rating and set a $235.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Barclays boosted their price objective on shares of Sarepta Therapeutics from $185.00 to $226.00 and gave the company an overweight rating in a report on Friday, June 21st. Finally, Royal Bank of Canada boosted their price objective on shares of Sarepta Therapeutics from $142.00 to $182.00 and gave the company a sector perform rating in a report on Friday, June 21st. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $187.72.

Sarepta Therapeutics Trading Down 0.7 %

SRPT opened at $153.11 on Monday. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The company has a market cap of $14.47 billion, a price-to-earnings ratio of 1,391.91 and a beta of 0.89. The firm has a 50 day simple moving average of $131.86 and a 200 day simple moving average of $123.74. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. Sarepta Therapeutics’s revenue for the quarter was up 63.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.44) earnings per share. On average, sell-side analysts anticipate that Sarepta Therapeutics will post 3.71 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In other news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares in the company, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. Insiders have sold a total of 50,451 shares of company stock valued at $8,086,386 over the last 90 days. 7.70% of the stock is owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Sarepta Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after acquiring an additional 243,180 shares in the last quarter. Capital International Investors raised its position in Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after acquiring an additional 76,032 shares in the last quarter. Avoro Capital Advisors LLC raised its position in Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after acquiring an additional 319,444 shares in the last quarter. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 5.6% during the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after acquiring an additional 217,810 shares in the last quarter. Finally, Farallon Capital Management LLC raised its position in Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.